Composition orale de la molsidomine à libération prolongée pour le traitement de l'athérosclérose

摘要

The present invention, which is applicable in the pharmaceutical industry, relates to the use of molsidomine or one of its pharmaceutically acceptable salts, especially in the form of a sustained-release solid oral composition effective over 24 hours, for the manufacture of a drug for preventing or reducing the development of atherosclerosis.